Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-111-7 | CAS number: 115-84-4
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
2-butyl-2-ethylpropanediol (BEPD) is likley to be rapidly and extensively absorbed following oral and dermal exposure, with absorption following dermal exposure less extensive and more prolonged. Extensive distribution in body fluids is predicted. BEPD is likely to be metabolised by sequential oxidation of the hydroxy grops and excreted rapidly in the urine. Bioaccumulation is unlikely.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 50
- Absorption rate - inhalation (%):
- 100
Additional information
No toxicokinetic data are available. An adequate assessment of the basic toxicokinetics of 2-butyl-2-ethylpropanediol (BEPD) can be made from the existing toxicity data and theoretical considerations, without the need for specific testing, in line with the REACH data requirements.
Absorption
Extensive oral absorption of 2-butyl-2-ethylpropanediol is predicted based on its molecular size, solubility, chemical structure and on the basis of experience with other alcohols. The 2-butyl-2-ethylpropanediol molecule additionally satisfies Lipinski's rule of 5 (OECD QSAR Toolbox). Oral absorption is demonstrated by the findings of the acute oral toxicity study and systemic effects in the 28 -day oral study. Absorption following inhalation exposure is also likely to be extensive. Dermal absorption is likely to be less extensive, but is likely to occur to some extent. The results of the acute dermal toxicity study support this theory. In the absence of any quantitative absorption data, default assumptions are made for the purposes of DNEL calculation.
Distribution
No data are available, however rapid and extensive distribution can be predicted based on the knowledge of other low molecular weight alcohols. Effects in the 28 -day adn 90 -day studies indicate distribution of BEPD and/or its metabolites to the liver and kidneys.
Metabolism
Sequential oxidative metabolism of the hydroxy groups is predicted, based on known metabolic reactions and the elucidated pathways for other alcohol compounds. The OECD QSAR Toolbox (liver metabolism simulator) predicts a total of 2 metabolites. Hepatic metabolism is indicated by the adaptive effects (hepatocyte hypertrophy) noted at high dose levels in the 28 -day study.
Excretion
Rapid and extensive renal excretion of 2-butyl-2-ethylpropanediol and its metabolites is likely, with no potential for bioaccumulation based on chemical properties and likely extensive metabolism. Renal excretion is indicated by effects seen at high dose levels in the 28 -day and 90 -day studies.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
